Amryt Pharma gets US Patent for Headline Drug

21 November, 2016

Amryt Pharma has been given a U.S. patent to start phase III studies of their drug in the U.S. The drug, Episalvan, is being developed to help with an orphan disease (see the previous post to learn more about orphan drugs and diseases) called epidermolysis bullosa (EB) and partial-thickness wounds. The company specialises in the development of novel treatments for patients suffering from orphan diseases. They have two other products currently in their pipeline. One of these drugs is to help patients with Cushing's disease. Prospects are looking up for this company as they move into 2017.

Read the Article:

http://www.irishexaminer.com/business/amryt-pharma-gets-us-patent-for-headline-drug-420910.html

Read more about Amryt:

http://www.amrytpharma.com/